Atlas Trials

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Clinical trial NCT03968848 · COMPLETED

Trial details

NCT number
NCT03968848
Sponsor
Acerta Pharma BV
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic ImpairmentHepatic InsufficiencyHealthy Subjects
Start date
2018-11-12
Primary completion
2019-03-13
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.